

Alirocumab Market Outlook 2030: Market Size, CAGR, Trends And Forecast Analysis

*The Business Research Company's
Alirocumab Market Report 2026 – Market
Size, Trends, And Global Forecast 2026-
2035*

LONDON, GREATER LONDON, UNITED
KINGDOM, June 29, 2026

/EINPresswire.com/ -- "The [alirocumab
market](#) has experienced significant

growth in recent years, driven by evolving healthcare needs and advancements in treatment options. As cardiovascular diseases continue to pose a major health challenge worldwide, the demand for effective lipid-lowering therapies like alirocumab is expanding rapidly. Let's explore the current market status, the factors propelling its growth, key players, and the outlook for the future.

Steady Expansion in Alirocumab Market Size Through 2025 and Beyond

The market for alirocumab is on a strong upward trajectory. From a valuation of \$2.1 billion in 2025, it is projected to increase to \$2.32 billion by 2026, representing a compound annual growth rate (CAGR) of 10.4%. This robust growth during the historical period has been fueled by a rise in LDL cholesterol prevalence, the increasing burden of cardiovascular diseases, limitations associated with statin therapy, early adoption of biologic treatments in lipid management, and updates in clinical guidelines targeting hypercholesterolemia. Looking ahead, the market is expected to expand even more rapidly, reaching \$3.48 billion by 2030 with a CAGR of 10.6%. This anticipated growth is supported by factors such as the aging global population, broadening PCSK9 inhibitor pipelines, wider reimbursement coverage for biologics, increased availability of home-based self-administration therapies, and the growth of cardiovascular preventive care programs.

Download a free sample of the alirocumab market report:

https://www.thebusinessresearchcompany.com/sample_request?id=48369847&type=smp&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Jun_PR

Factors Behind the Surge in [Alirocumab Market Demand](#)

The rising occurrence of cardiovascular diseases stands out as a primary driver of the



alirocumab market's growth. Cardiovascular diseases encompass conditions affecting the heart and blood vessels, including coronary artery disease, cerebrovascular disease, and heart failure, all of which impair blood and oxygen circulation. One significant contributor to the increasing prevalence of these conditions is the widespread adoption of sedentary lifestyles. Reduced physical activity leads to metabolic issues, excess body fat accumulation, and the development of risk factors such as hypertension and dyslipidemia, which collectively elevate the risk of cardiovascular complications. Alirocumab acts by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9), effectively lowering LDL cholesterol levels and helping to reduce cardiovascular risk in affected populations. For example, in June 2024, the American Heart Association projected that cardiovascular disease prevalence among U.S. adults will climb from about 50% currently to 61% by 2050, underscoring the demand for more effective treatments like alirocumab.

Growing Influence of Personalized Medicine Boosts Market Growth

Another key element driving the alirocumab market is the increasing adoption of personalized medicine approaches. Personalized medicine customizes treatments based on individual patient factors such as genetics, biomarkers, lifestyle, and specific disease characteristics to enhance effectiveness and reduce side effects. Advances in genetic profiling have enabled clinicians to better understand disease predispositions and treatment responses, facilitating more precise therapeutic decisions. Alirocumab fits well within this paradigm as a targeted lipid-lowering therapy, especially useful for patients with genetic lipid disorders or those who do not respond adequately to conventional treatments, thus improving individualized cardiovascular risk management. A relevant example is a February 2024 report by the Personalized Medicine Coalition, which highlighted that over one-third of new drug approvals by the U.S. Food and Drug Administration between 2020 and 2023 were personalized therapies. In 2023 alone, approvals included 16 treatments for rare diseases, seven oncology drugs, and others targeting various conditions, reflecting the rising focus on precision medicine.

View the full alirocumab market report:

https://www.thebusinessresearchcompany.com/report/alirocumab-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Jun_PR

Global Regional Outlook for the Alirocumab Market

In terms of geographical distribution, North America held the largest share of the alirocumab market in 2025, benefiting from advanced healthcare infrastructure and reimbursement policies. Meanwhile, the Asia-Pacific region is poised to witness the fastest growth over the forecast period, driven by increasing healthcare access, expanding patient populations, and growing awareness of cardiovascular disease management. The comprehensive market analysis covers key regions such as Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, and the Middle East and Africa, offering a broad perspective on global market trends and opportunities.

New additions to our 2026 reports:

- Market attractiveness scoring and analysis
- Total addressable market (TAM) analysis
- Company scoring matrix graphics and tables
- Excel-based forecasting dashboards
- Market hotspots infographics
- Key technologies and future trend analysis
- Updated graphics and tables

Speak With Our Expert:

Saumya Sahay

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email: marketing@tbrc.info

[The Business Research Company](http://www.thebusinessresearchcompany.com) - www.thebusinessresearchcompany.com

Follow Us On:

- LinkedIn: <https://in.linkedin.com/company/the-business-research-company>"

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/923020727>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.